Survivin suppression through STAT3/β-catenin is essential for resveratrol-induced melanoma apoptosis

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 895-901

  Habibie, ^a   Yokoyama, Satoru ^a   Abdelhamed, Sherif ^a   Awale, Suresh ^a   Sakurai, Hiroaki ^a,b   Hayakawa, Yoshihiro ^a   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Melanoma; Resveratrol; Survivin

Indexed keywords

BCL2 RELATED PROTEIN A1; BETA CATENIN; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RESVERATROL; STAT3 PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902581796     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2480     Document Type: Article

References (35)

1. Chudnovsky Y, Khavari PA and Adams AE: Melanoma genetics and the development of rational therapeutics. J Clin Invest 115: 813-824, 2005.
2. Jemal A, Devesa SS, Fears TR and Hartge P: Cancer surveillance series: changing patterns of cutaneous malignant melanoma mortality rates among whites in the United States. J Natl Cancer Inst 92: 811-818, 2000.
3. Jemal A, Devesa SS, Hartge P and Tucker MA: Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 93: 678-683, 2001.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
5. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
6. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
7. Nashan D, Muller ML, Grabbe S, Wustlich S and Enk A: Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 21: 1305-1318, 2007.
8. Petrovski G, Gurusamy N and Das DK: Resveratrol in cardiovascular health and disease. Ann NY Acad Sci 1215: 22-33, 2011.
9. Szkudelska K and Szkudelski T: Resveratrol, obesity and diabetes. Eur J Pharmacol 635: 1-8, 2010.
10. Signorelli P and Ghidoni R: Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16:449-466, 2005.
11. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
12. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM and Meadows GG: Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 190: 157-163, 2003.
13. Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23: 6702-6711, 2004.
14. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H and Hei TK: Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314: 1163-1176, 2008.
15. Fulda S and Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-346, 2004.
16. Fang Y, Bradley MJ, Cook KM, Herrick EJ and Nicholl MB: A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J Surg Res 183: 645-653, 2013.
17. Kim MY: Nitric oxide triggers apoptosis in A375 human melanoma cells treated with capsaicin and resveratrol. Mol Med Rep 5: 585-591, 2012.
18. Osmond GW, Augustine CK, Zipfel PA, Padussis J and Tyler DS: Enhancing melanoma treatment with resveratrol. J Surg Res 172: 109-115, 2012.
19. Tak JK, Lee JH and Park JW: Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep 45: 242-246, 2012.
20. Sakurai H, Suzuki S, Kawasaki N, et al: Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278: 36916-36923, 2003.
21. Haq R, Yokoyama S, Hawryluk EB, et al: BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110: 4321-4326, 2013.
22. Trapp V, Parmakhtiar B, Papazian V, Willmott L and Fruehauf JP: Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 13: 305-315, 2010.
23. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70, 2008.
24. Zhang J, Chiu J, Zhang H, et al: Autophagic cell death induced by resveratrol depends on the Ca(2+)/AMPK/mTOR pathway in A549 cells. Biochem Pharmacol 86: 317-328, 2013.
25. Jiang H, Shang X, Wu H, et al: Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 8: 25-33, 2009.
26. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26: 2678-2684, 2007.
27. Zhao W, Bao P, Qi H and You H: Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPC-A-1/CDDP cells. Oncol Rep 23: 279-286, 2010.
28. Hayashibara T, Yamada Y, Nakayama S, et al: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer 44: 193-201, 2002.
29. Shankar S, Siddiqui I and Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 304: 273-285, 2007.
30. Singh SK, Moretta D, Almaguel F, Wall NR, De Leon M and De Leon D: Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25: 363-372, 2007.
31. Singh RP, Tyagi A, Sharma G, Mohan S and Agarwal R: Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 14: 300-308, 2008.
32. Talantov D, Mazumder A, Yu JX, et al: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11: 7234-7242, 2005.
33. Velculescu VE, Madden SL, Zhang L, et al: Analysis of human transcriptomes. Nat Genet 23: 387-388, 1999.
34. Adhami VM, Afaq F and Ahmad N: Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia 5: 74-82, 2003.
35. Widlund HR, Horstmann MA, Price ER, et al: Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158: 1079-1087, 2002.